Drug Trial Radar · NCT05328908
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
769
Actual
Start
Apr 28, 2022
Primary completion
Jul 14, 2025
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.
Conditions
- Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDCDrug
Specified dose on specified days
RegorafenibDrug
Specified dose on specified days
TAS-102Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization to the date of death due to any cause (Up to approxaimtely 38 months)
Locations
139 sites in 22 countries. Site status is shown where the registry gives one.
Local Institution - 0044
Springdale, Arkansas
Local Institution - 0012
Los Angeles, California
Local Institution - 0117
Norwich, Connecticut
Local Institution - 0025
Miami, Florida
Local Institution - 0031
Atlanta, Georgia
Local Institution - 0071
Boise, Idaho
Local Institution - 0081
Fort Wayne, Indiana
Massachusetts General Hospital,
Boston, Massachusetts
Local Institution - 0042
Ann Arbor, Michigan
Local Institution - 0043
East Brunswick, New Jersey
Local Institution - 0009
Durham, North Carolina
Local Institution - 0082
Cincinnati, Ohio
Local Institution - 0095
Columbus, Ohio
Local Institution - 0147
Philadelphia, Pennsylvania
Local Institution - 0008
Charleston, South Carolina
Local Institution - 0096
Sioux Falls, South Dakota
Local Institution - 0127
Nashville, Tennessee
Local Institution - 0097
Fort Worth, Texas
Local Institution - 0132
Richmond, Virginia
Local Institution - 0005
Madison, Wisconsin
Local Institution - 0024
Ciudad Autónoma Buenos Aires, Argentina
Local Institution - 0023
Rio Grande, Argentina
Local Institution - 0026
Ciudad Autónoma Buenos Aires, B, Argentina
Local Institution - 0022
Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina
Local Institution - 0098
Wagga Wagga, New South Wales, Australia
Local Institution - 0114
Westmead, New South Wales, Australia
Local Institution - 0001
Greenslopes, Queensland, Australia
Local Institution - 0010
Clayton, Victoria, Australia
Local Institution - 0021
Melbourne, Victoria, Australia
Local Institution - 0027
Murdoch, Western Australia, Australia
Local Institution - 0030
Graz, Austria
Local Institution - 0078
Klagenfurt, Austria
Local Institution - 0131
Salzburg, Austria
Local Institution - 0070
Edegem, Belgium
Local Institution - 0120
Leuven, Belgium
Local Institution - 0062
Woluwé-Saint-Lambert, BRU, Belgium
Local Institution - 0068
Ghent, VOV, Belgium
Local Institution - 0003
Edmonton, Alberta, Canada
Local Institution - 0014
Ottawa, Ontario, Canada
Local Institution - 0007
Toronto, Ontario, Canada
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.